Antheia Secures Additional $9M In Expanded BioMaP-Consortium Project Agreement To Onshore Pharmaceutical Supply Chains

The award, funded by the U.S. Department of Health and Human Services’ (HHS) Defense Production Act (DPA) Title III Program, serves as continued validation of the federal government’s commitment to onshoring pharmaceutical supply chains.
Antheia Secures Additional Funding from HHS to Onshore Supply Chains

Antheia, a biosynthesis company delivering pharmaceutical manufacturing and innovation, has expanded the scope of its second project agreement with the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), securing an additional $9 million.
Antheia Secures Additional $9 Million in Expanded BioMaP-Consortium Project Agreement to Onshore Pharmaceutical Supply Chains
U.S. government fortifies commitment to advanced manufacturing technology for the domestic production of essential medicines MENLO PARK, Calif., March 4, 2026 – Antheia, the advanced biosynthesis company delivering 21st-century pharmaceutical manufacturing and innovation, today announced it has expanded the scope of its second project agreement with the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), securing an additional $9 million. The additional funds bring the total project investment to $21 […]